Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Excluding sales from REGEN-COV, Regeneron's revenue for the year grew by 19% year over year. While that's a lot less impressive, it is still an excellent performance.

Regeneron Pharmaceuticals is hoping to establish itself as a major oncology player. See why I no longer see REGN stock price upside in the near term.

This was the stock's fourth consecutive day of gains.

Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that ...

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.